Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.
Landi D, Ragonese P, Prosperini L, Nociti V, Haggiag S, Cortese A, Fantozzi R, Pontecorvo S, Ferraro E, Buscarinu MC, Mataluni G, Monteleone F, Salvetti M, Di Battista G, Francia A, Millefiorini E, Gasperini C, Mirabella M, Salemi G, Boffa L, Pozzilli C, Centonze D, Marfia GA. Landi D, et al. Among authors: pontecorvo s. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1272-1278. doi: 10.1136/jnnp-2018-318468. Epub 2018 Jul 3. J Neurol Neurosurg Psychiatry. 2018. PMID: 29970387
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.
Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C. Prosperini L, et al. Among authors: pontecorvo s. J Neurol. 2017 Feb;264(2):284-294. doi: 10.1007/s00415-016-8343-5. Epub 2016 Nov 22. J Neurol. 2017. PMID: 27878443
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M. Prosperini L, et al. Among authors: pontecorvo s. Neurology. 2018 Jul 10;91(2):e153-e161. doi: 10.1212/WNL.0000000000005772. Epub 2018 Jun 6. Neurology. 2018. PMID: 29875218 Clinical Trial.
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. Among authors: pontecorvo s. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study.
Prosperini L, Cortese A, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Capone F, Centonze D, De Fino C, De Pascalis D, Fantozzi R, Ferraro E, Filippi M, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia G, Mataluni G, Millefiorini E, Mirabella M, Monteleone F, Nociti V, Pontecorvo S, Romano S, Ruggieri S, Salvetti M, Tortorella C, Zannino S, Di Battista G. Prosperini L, et al. Among authors: pontecorvo s. J Neurol. 2020 Mar;267(3):694-702. doi: 10.1007/s00415-019-09625-1. Epub 2019 Nov 13. J Neurol. 2020. PMID: 31720848
From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study.
Prosperini L, Mancinelli CR, Pozzilli C, Grasso MG, Clemenzi A, Collorone S, Pontecorvo S, Francia A, Villani V, Koudriavtseva T, Buttari F, Centonze D, Di Battista G, Frisullo G, Galgani S, Gasperini C. Prosperini L, et al. Among authors: pontecorvo s. Eur Neurol. 2014;71(5-6):233-41. doi: 10.1159/000356786. Epub 2014 Jan 25. Eur Neurol. 2014. PMID: 24480868
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.
Chisari CG, Solaro C, Annunziata P, Bergamaschi R, Bianco A, Bonavita S, Brescia Morra V, Bruno Bossio R, Capello E, Castelli L, Cavalla P, Costantino G, Centonze D, Cottone S, Danni MC, Esposito F, Gajofatto A, Gasperini C, Guareschi A, Lanzillo R, Lus G, Maniscalco GT, Matta M, Paolicelli D, Petrucci L, Pontecorvo S, Righini I, Rovaris M, Sessa E, Spinicci G, Spitaleri D, Valentino P, Zaffaroni M, Zappia M, Patti F. Chisari CG, et al. Among authors: pontecorvo s. J Neurol Neurosurg Psychiatry. 2020 Sep;91(9):914-920. doi: 10.1136/jnnp-2019-322480. Epub 2020 Jul 13. J Neurol Neurosurg Psychiatry. 2020. PMID: 32661083
Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
Iannetta M, Zingaropoli MA, Bellizzi A, Morreale M, Pontecorvo S, D'Abramo A, Oliva A, Anzivino E, Lo Menzo S, D'Agostino C, Mastroianni CM, Millefiorini E, Pietropaolo V, Francia A, Vullo V, Ciardi MR. Iannetta M, et al. Among authors: pontecorvo s. PLoS One. 2016 Aug 3;11(8):e0160277. doi: 10.1371/journal.pone.0160277. eCollection 2016. PLoS One. 2016. PMID: 27486658 Free PMC article. Clinical Trial.
36 results